Protease inhibitor-based regimens for HIV therapy: Safety and efficacy

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue SUPPL. 1, 2007, Pages

  Walmsley, Sharon ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiretrovirals; Atazanavir; Fosamprenavir; HIV; Lopinavir; Protease inhibitors; Saquinavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; SAQUINAVIR;

CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG POTENCY; DRUG TOLERABILITY; DRY SKIN; EVIDENCE BASED PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; LIPODYSTROPHY; NAUSEA; PARONYCHIA; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; VOMITING;

HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 34249691283     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180600709     Document Type: Review

References (76)

1. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-1017.
2. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
5. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659-665.
6. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1995;345:952-955.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
8. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
9. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
10. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
11. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546-550.
12. Paton NI, Earnest A, Ng YM, et al. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis. 2002;35:1244-1249.
13. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
15. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
16. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
17. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:538-539.
18. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
19. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2006.
20. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001;2:105-113.
21. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6:421-425.
22. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-39.
23. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-642.
24. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.
25. Stryker R, Brun S, King M, et al. Kaletra (ABT-378/ritonavir) in antiretroviral-naive HIV+ patients: follow-up beyond two years and viral load suppression below 3 copies/mL. Presented at: Fifth International Congress on Drug Therapy in HIV Infection; 2000; Glasgow.
26. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
27. The AVANTI Study Group. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS. 2000;14:367-374.
28. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of Thymidine Analog Regimen Therapy (START I). AIDS. 2000;14:1591-1600.
29. Eron JJ, Murphy RL, Peterson D, et al, for the START II Study Team. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of Thymidine Analog Regimen Therapy (START II). AIDS. 2000;14:1601-1610.
30. Goodgame J, Pottage JC, Jablonowski H, et al, for the Amprenavir PROAB3001 International Study Team. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Antivir Ther. 2000;5:215-225.
31. Murphy R, daSilva B, McMillan F, et al. Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects [poster PE7.9/3]. Presented at: 10th European AIDS Conference; 2005; Dublin.
32. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
33. Ruane P, Mendonca J, Timerman A, et al. Kaletra vs nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial. Presented at: International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires.
34. King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004;190:280-284.
35. Molina JM, Wilkin A, Domingo P. Once daily vs twice daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results. Presented at: International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro.
36. Pollard RB, Thompson M, Hicks C. Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitor in single-PI experienced, NNRTI-naive patients: 48 week results of study M98-888. Presented at: Seventh International Congress on Drug Therapy in HIV Infections; 2004; Glasgow.
37. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
38. Dupon M, Livrozet JM, Morand-Joubert L, et al. Lipid profile of lopinavir/ritonavir (LPV/r) in an 18-month French observational prospective cohort (Kaleobs cohort) [poster P133]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
39. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; 2005.
40. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
41. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
42. Bernstein B, King M, Brun S. Safety of Kaletra data from phase II and phase III clinical trials (M98-863, M97-765, M97-957). Presented at: International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires.
43. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-7469.
44. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
45. Gathe JC Jr, Lipman BA, Mayberry C, et al. Tolerability and therapy preference of lopinavir/ritonavir (Kaletra) soft-gel capsules and tablets as single agent in a cohort of HIV positive adult patients (IMANI-2) [poster P62]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
46. Schrader S, Chuck SK, Rahn LW, et al. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir after switching from BID soft-gel capsule (SGC) to BID tablets [poster P104]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
47. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537.
48. Hicks C, DeJesus E, Sloan L, et al. Efficacy and safety of once-daily boosted fosamprenavir/ritonavir (FPV/r) with abacavir(ABC)/lamivudine (3TC) fixed dose combination in antiretroviral-naive HIV-1 infected patients: 24-week results from COL100758 [poster P2]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
49. Smith K, Weinberg W, DeJesus E, et al. Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT) [poster P1]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
50. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-465.
51. Ananworanich J, Hill A, Siangphoe U, et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther. 2005;10:761-767.
52. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther. 2006;11:631-635.
53. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735-743.
54. Slim J, Avihingsanon A, Ruxrungtham K, et al. Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naive HIV-1 infected patients: GEMINI Study [poster PL2.5]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
55. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-2614.
56. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-1019.
57. Malan N, Krantz E, David N, et al, for the AI424-089 Study Group. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
58. McGrath D, Hammond J, Frederick D, et al. Evaluation of resistance patterns in treatment-naive subjects with virological failure on atazanaviror atazanavir/ritonavir-containing regimens [abstract 87]. Antivir Ther. 2006;11:S97.
59. Bristol-Myers Squibb. New 48 week clinical trial data reported comparing Reyataz (atazanavir sulfate), with or without ritonavir, in treatment-naive patients [press release]. Princeton, NJ: Bristol-Myers Squibb; 2006.
60. DeWit S, Poll B, Nescoi C, et al. Atazanavir has a better impact on lipid profiles than fosamprenavir and lopinavir in patients matched for baseline triglycerides and cholesterol [poster P127]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
61. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
62. Elion R, DeJesus E, Sension M, et al. Once-daily (QD) abacavir (ABC)/lamivudine (3TC) and ritonavir-boosted atazanavir (ATV/r) in antiretroviral naive HIV-1 infected subjects: 24-week analysis from COL10206 (SHARE) [poster P10]. Presented at: Eighth International Congress on Drug Therapy in HIV Infections; 2006; Glasgow.
63. Riddler SA, Haubrich RH, Dirienzo G. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infections - ACTG 5142. Presented at: 16th International AIDS Conference; 2006; Toronto.
64. Kuritzkes D, Lalama C, Ribaudo H, et al. Baseline resistance to NNRTI as a predictor of virologic failure in treatment-naive subjects receiving efavirenz-based regimens in ACTG A5095. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
65. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41:323-331.
66. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451-458.
67. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
68. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
69. Haubrich RH, Riddler S, DiRienzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
70. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
71. Mildvan D, Tierney C, Gross R, et al. Randomized comparison in treatment-naive patients of once-daily vs. twice-daily lopinavir/ritonavir-based ART and comparison of once-daily self-administered vs. directly observed therapy. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
72. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. A randomized controlled, open label, pilot, clinical trial (OK Study): 48 week analysis. Presented at: International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro.
73. Arribas J, Pulido F, Delgado R, et al. Drug resistance outcomes at 48 weeks in the OK04 trial: a comparative trial of single-drug maintenance therapy with lopinavir/ritonavir vs. triple therapy with lopinavir/ritonavir. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
74. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-814.
75. Cameron W, Da Silva DM, Arribas J. A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir monotherapy after initial induction treatment compared to an efavirenz 3-drug regimen (study M03-613). Presented at: 16th International AIDS Conference; 2006; Toronto.
76. Delfraissy JF, Flandre P, Delaugerre C. MONARK trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir monotherapy compared to LPV/r + zidovudine/lamivudine in antiretroviral-naive patients. Presented at: 16th International AIDS Conference; 2006; Toronto.